#Spain #Barcelona #pharmaceutical #CDMO #ESTEVE

ESTEVE's Expansion and Growth in the EU and the USA

ESTEVE, a healthcare company based in Barcelona, has announced impressive growth figures for the year 2025, fueled by strong strategic execution and double-digit revenue increases. The company achieved a notable 14% rise in net revenues and a 19% increase in EBITDA compared to 2024, emphasizing its solid financial performance.

Key Developments and Strategies

In its pursuit to establish itself as a global leader in healthcare, ESTEVE has focused on expanding its pharmaceutical and Contract Development and Manufacturing Organization (CDMO) segments. The company has successfully added eight new specialized products to its portfolio over the past 18 months, signifying its commitment to targeting patient populations with unmet needs, particularly in oncology and endocrinology.

One of the key strategic moves this year was the acquisition of TerSera, a U.S.-based pharmaceutical unit known for two highly specialized drugs. This acquisition, along with others, has strengthened ESTEVE's pharmaceutical offerings, reinforcing its focus on high-complexity diseases. Furthermore, the recent purchase of Regis Technologies has enhanced ESTEVE's early-stage development capabilities within its CDMO operations, a vital step in increasing its footprint in the world's largest pharmaceutical market.

Financial Performance

The figures reported illustrate the effectiveness of ESTEVE's dual business model, with both the pharmaceutical and CDMO arms reporting similar growth rates. In 2025, the company reported a revenue of €828 million, maintaining a strong EBITDA margin of 18%. This performance is attributed to ESTEVE's disciplined approach towards investment in innovation and operational excellence.

The company's commitment to high levels of investment was evident as it allocated €49 million for product process and technology development, reflecting a 7% increase year-on-year. In total, ESTEVE has invested approximately €500 million over the last two years, which has been used to enhance its specialized drug offerings and expand CDMO production capabilities.

Commitment to ESG and Corporate Responsibility

In addition to its financial success, ESTEVE has made significant strides in its environmental and social governance (ESG) commitments, earning B Corp certification. This certification underscores the company's dedication to social and environmental impact, transparency, and accountability in its business operations. ESTEVE's ongoing initiatives have included unified ESG policies and a clear roadmap towards achieving Net Zero.

The company has bolstered its social commitment by supporting patient associations and healthcare facilities, positively impacting hundreds of thousands globally. ESTEVE's results reflect a highly engaged workforce, with a record employee engagement score of 87%, showcasing the company’s strong corporate culture centered on human values, transparency, and responsibility.

Future Outlook

Looking ahead, ESTEVE aims to reach a net revenue of €1 billion by 2027 through both organic and inorganic growth strategies focused on both its pharmaceutical and CDMO sectors. This ambitious target aligns with its broader vision of becoming a key player in global healthcare, aiming to enhance lives through collaboration and innovation.

Founded in 1929, ESTEVE has expanded its operations globally, with pharmaceutical subsidiaries in Europe and the U.S., and CDMO facilities located across Spain, Mexico, China, and the United States. ESTEVE remains steadfast in its mission to improve lives with its specialized healthcare solutions and innovative drug technologies.

For more information on ESTEVE, please visit www.esteve.com.